Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin–DNA adduct formation in patients and ovarian cancer cell lines
P.J.M. van de Vaart(The Netherlands Cancer Institute), Adrian C. Begg(The Netherlands Cancer Institute), Jos H. Beijnen(The Netherlands Cancer Institute), F.A.N. Zoetmulder(The Netherlands Cancer Institute), W.W. ten Bokkel Huinink, Nine van der Vange(Amsterdam UMC Location University of Amsterdam), A.R. van Goethem(The Netherlands Cancer Institute), Harry Bartelink(Radboud University Nijmegen), Olaf van Tellingen(Dutch Cancer Society)
Cited by 233
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial
|Journal of Clinical Oncology|2007|1k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer
|New England Journal of Medicine|2015|1k